NeuroMab™ Anti-CD38 BBB Shuttle Antibody (NRZP-1022-ZP3883)
- Host Species:
- Humanized
- Species Reactivity:
- Human
- Applications:
- ADCC; CDC; FC; In Vitro
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.
Species Reactivity
Clonality
Host Species
Applications
Storage
Research Use Only
Target
Official Name
Full Name
Alternative Names
ADP ribosyl cyclase 1;
ADP ribosyl cyclase;
ADP ribosyl cyclase/cyclic ADP-ribose hydrolase;
ADP-ribosyl cyclase 1;
ADPRC 1;
ADPRC1;
cADPr hydrolase 1;
CD 38;
Figure 1A CDC mediated by CD38 antibody HuMAb 005 mutant on CD38 positive cells.
Figure 1A CDC efficacy of a series of 005 mutants on Daudi cells.
Figure 1B CDC mediated by the CD38 antibody HuMAb 005 mutant on CD38-positive cells.
1B CDC efficacy of HuMAb 005 mutants at a range of concentrations on Raji cells.
Figure 2 CDC of wild-type and E345R mutants of the CD38 antibody HuMAb 005 in competition experiments with Fc-binding peptides.
Figure 3 ADCC of wild-type CD38 antibody HuMAb 005 and mutant IgG1-005-E345R on CD38-expressing Daudi cells. ADCC of PBMC from one donor is shown, depicted as percent lysis.
Figure 4 CDC on CD20 and CD38 positive Wien133 cells.
Figure 5 CDC on CD20 and CD38 positive Wien133 cells.
Figure 6 In vivo efficacy assessment of IgG1-005-E345R in a subcutaneous xenograft model with Raji-luc #2D1 cells.
Figure 7 In vivo efficacy assessment of IgG1-005-E345R in a subcutaneous xenograft model with Raji-luc #2D1 cells.
Figure 8A Introduction of the Fc-Fc stabilizing E345R mutation in wild-type CD38 antibody 005 resulted in enhanced killing of primary CLL cells in an ex vivo CDC assay (mean ± standard error of the mean).
Figure 8B Introduction of the Fc-Fc stabilizing E345R mutation in wild-type CD38 antibody 005 resulted in enhanced killing of primary CLL cells in an ex vivo CDC assay (mean ± standard error of the mean).
Publications (0)
